Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.

@article{Bonadonna2013VenomII,
  title={Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.},
  author={Patrizia Bonadonna and David Gonz{\'a}lez-de-Olano and Roberta Zanotti and Annamaria Riccio and Laura De Ferrari and Carla Lombardo and Anthi Rogkakou and L. M. Escribano and Iv{\'a}n {\'A}lvarez-Twose and Almudena Matito and Arantza Vega and Giovanni Passalacqua},
  journal={The journal of allergy and clinical immunology. In practice},
  year={2013},
  volume={1 5},
  pages={474-8}
}
BACKGROUND A preferential association between systemic mastocytosis (SM) and hymenoptera allergy (HVA) has been observed. Patients with both diseases are at risk for more severe reactions, and venom immunotherapy (VIT) may represent a life-saving treatment, but the use of VIT in such patients raised concerns about its safety. OBJECTIVE We evaluated a large population of patients with SM and HVA who received VIT. METHODS This prospective study was performed in Italy and Spain. A diagnosis of… CONTINUE READING